FDA Grants Breakthrough Designation for Nyxoah Genio System

The FDA will provide the Genio system with priority review and interaction with FDA’s experts throughout the premarket review phase until the product is commercialized in the United States.

Related Keywords

United States , Olivier Taelman , Breakthrough Designation Program , Drug Administration , Breakthrough Device Designation , Designation Program , Breakthrough Designation , Eral Hypoglossal Nerve Stimulation ,